27,863 Shares in Assembly Biosciences, Inc. $ASMB Bought by 683 Capital Management LLC

683 Capital Management LLC purchased a new position in Assembly Biosciences, Inc. (NASDAQ:ASMB) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 27,863 shares of the biopharmaceutical company’s stock, valued at approximately $948,000. 683 Capital Management LLC owned 0.18% of Assembly Biosciences as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bank of America Corp DE grew its stake in Assembly Biosciences by 6,382.7% in the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 3,319 shares during the period. Acadian Asset Management LLC boosted its holdings in Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 6,823 shares in the last quarter. Charles Schwab Investment Management Inc. bought a new stake in Assembly Biosciences in the fourth quarter worth $228,000. Qube Research & Technologies Ltd bought a new stake in Assembly Biosciences in the third quarter worth $282,000. Finally, ADAR1 Capital Management LLC bought a new stake in Assembly Biosciences in the third quarter worth $485,000. 19.92% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on ASMB. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a report on Monday, May 4th. Mizuho set a $45.00 target price on Assembly Biosciences and gave the stock an “outperform” rating in a report on Monday. Wall Street Zen downgraded Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Guggenheim reaffirmed a “buy” rating and set a $43.00 price target on shares of Assembly Biosciences in a report on Thursday, May 28th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a report on Monday, April 20th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Assembly Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $44.00.

Assembly Biosciences Stock Performance

Assembly Biosciences stock opened at $24.15 on Thursday. The stock has a market cap of $383.74 million, a PE ratio of -219.53 and a beta of 1.07. Assembly Biosciences, Inc. has a one year low of $16.50 and a one year high of $39.71. The stock has a fifty day moving average of $27.32 and a 200 day moving average of $29.15.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.11. The company had revenue of $8.21 million during the quarter, compared to analysts’ expectations of $9.27 million. Assembly Biosciences had a negative return on equity of 4.21% and a negative net margin of 8.98%. As a group, sell-side analysts predict that Assembly Biosciences, Inc. will post 1.9 EPS for the current fiscal year.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.